Dipòsit Digital de Documents de la UAB 5 registres trobats  La cerca s'ha fet en 0.00 segons. 
1.
14 p, 9.2 MB Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1 -Mutant Myelodysplastic Syndromes With Ringed Sideroblasts / Ademà, Vera (The University of Texas MD Anderson Cancer Center) ; Ma, Feiyang (University of Michigan) ; Kanagal-Shamanna, Rashmi (The University of Texas MD Anderson Cancer Center) ; Thongon, Natthakan (The University of Texas MD Anderson Cancer Center) ; Montalban-Bravo, Guillermo (The University of Texas) ; Yang, Hui (The University of Texas) ; Peslak, Scott A. (Children's Hospital of Philadelphia (Pennsilvània)) ; Wang, Feng (The University of Texas MD Anderson Cancer Center) ; Acha, Pamela (Universitat Autònoma de Barcelona) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Lockyer, Pamela (The University of Texas MD Anderson Cancer Center) ; Cassari, Margherita (University of Florence) ; Maciejewski, Jaroslaw P. (Cleveland Clinic Foundation) ; Visconte, Valeria (Cleveland Clinic Foundation) ; Gañán-Gómez, Irene (The University of Texas MD Anderson Cancer Center) ; Song, Yuanbin (Sun Yat-sen University Cancer Center) ; Bueso-Ramos, Carlos (The University of Texas MD Anderson Cancer Center) ; Pellegrini, Matteo (University of California) ; Tan, Tuyet M. (Univerity of California San Diego) ; Bejar, Rafael (Univerity of California San Diego) ; Carew, Jennifer S. (University of Arizona Cancer Center) ; Halene, Stephanie (Yale University School of Medicine) ; Santini, Valeria (University of Florence) ; Al-Atrash, Gheath (The University of Texas MD Anderson Cancer Center) ; Clise-Dwyer, Karen (The University of Texas MD Anderson Cancer Center) ; Garcia-Manero, Guillermo (The University of Texas MD Anderson Cancer Center) ; Blobel, Gerd A. (Children's Hospital of Philadelphia (Pennsilvània)) ; Colla, Simona (The University of Texas MD Anderson Cancer Center)
SF3B1 -mutant MDS-RS is associated with buildup of erythroid progenitor cells upregulating EIF2AK1-associated heme deficiency response and autophagy genes. Targeting EIF2AK1 relieves the dysregulated progenitor phenotype. [...]
2022 - 10.1158/2643-3230.BCD-21-0220
Blood Cancer Discovery, Vol. 3 (august 2022) , p. 554-567  
2.
13 p, 3.0 MB Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q / Ademà, Vera (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute) ; Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Walter, Wencke (Munich Leukemia Laboratory) ; Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hutter, Stephan (Munich Leukemia Laboratory) ; La Framboise, Thomas (Department of Genetics and Genome Sciences. Case Western Reserve University) ; Arenillas, Leonor (Institut Hospital del Mar d'Investigacions Mèdiques) ; Meggendorfer, Manja (Munich Leukemia Laboratory) ; Radivoyevitch, Tomas (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Pellagatti, Andrea (Blood Cancer UK Molecular Haematology Unit. Nuffield Division of Clinical Laboratory Sciences. Radcliffe Department of Medicine. University of Oxford and Oxford BRC Haematology Theme) ; Haferlach, Claudia (Munich Leukemia Laboratory) ; Boultwood, Jacqueline (University of Oxford. Radcliffe Department of Medicine) ; Kern, Wolfgang (Munich Leukemia Laboratory) ; Visconte, Valeria (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute) ; Sekeres, Mikkael (Leukemia Program. Department of Hematology and Medical Oncology. Cleveland Clinic. Cleveland Clinic Taussig Cancer Institute) ; Barnard, John (Department of Quantitative Health Sciences. Cleveland Clinic. Lerner Research Institute) ; Haferlach, Torsten (Munich Leukemia Laboratory) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Maciejewski, Jaroslaw (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute)
Background: Haploinsufficiency (HI) resulting from deletion of the long arm of chromosome 5 [del(5q)] and the accompanied loss of heterozygosity are likely key pathogenic factors in del(5q) myeloid neoplasia (MN) although the consequences of del(5q) have not been yet clarified. [...]
2022 - 10.1016/j.ebiom.2022.104059
EBioMedicine, Vol. 80 (june 2022) , art. 104059  
3.
469.5 KB Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes / Martin, Roman (University Medical Center Göttingen) ; Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ganster, Christina (University Medical Center Göttingen) ; Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Dierks, Sascha (University Medical Center Göttingen) ; Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ademà, Vera (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gómez-Marzo, Paula (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; De Haro, Nuri (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Solanes, Neus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Shirneshan, Katayoon (University Medical Center Göttingen) ; Flach, Johanna (University Medical Center Göttingen) ; Braulke, Friederike (University Medical Center Göttingen) ; Schanz, Julie (University Medical Center Göttingen) ; Kominowski, Arkadiusz (University Medical Center Göttingen) ; Stromburg, Martin (University Medical Center Göttingen) ; Brockmann, Alina (University Medical Center Göttingen) ; Trümper, Lorenz (University Medical Center Göttingen) ; Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Haase, Detlef (University Medical Center Göttingen) ; Universitat Autònoma de Barcelona
2018 - 10.1002/ajh.25089
American Journal of Hematology, Vol. 93 (april 2018) , p. E152-E154  
4.
15 p, 2.2 MB Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features / Palomo Sanchís, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; García, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Arnan, Montserrat (Institut Català d'Oncologia) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Fuster García, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cabezón, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Coll, Rosa (Hospital Universitari de Girona Doctor Josep Trueta) ; Ademà, Vera (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Grau Cat, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Jiménez, Maria-José (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Pomares, Helena (Institut Català d'Oncologia) ; Marcé, Silvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Millá, Fuensanta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Alonso, Esther (Institut Català d'Oncologia) ; Sureda, Anna (Institut Català d'Oncologia) ; Gallardo, David (Hospital Universitari de Girona Doctor Josep Trueta) ; Feliu Frasnedo, Evarist (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Clonal cytogenetic abnormalities are found in 20-30% of patients with chronic myelomonocytic leukemia (CMML), while gene mutations are present in >90% of cases. Patients with low risk cytogenetic features account for 80% of CMML cases and often fall into the low risk categories of CMML prognostic scoring systems, but the outcome differs considerably among them. [...]
2016 - 10.18632/oncotarget.10937
Oncotarget, Vol. 7, Num. 35 (August 2016) , p. 57021-57035  
5.
277 p, 4.1 MB Estudio de perfiles moleculares en pacientes con síndrome mielodisplásico / Ademà, Vera ; Barrios, Leonardo, tut. (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Solé Ristol, Francisco, dir. ; Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia
Los SÍNDROMES MIELODISPLÁSICOS (SMD) son una enfermedad heterogénea clonal de células madre hematopoyéticas. Se caracteriza por una medula ósea ineficaz que produce citopenias en sangre periférica. [...]
MYELODYSPLASTIC SYNDROMES are clonal hematopoietic stem cell disorders highly heterogeneous. This disease is characterized by bone marrow failure that led to peripheral blood citopenias. The outcome of these patients is closely related to cytopenias and to an increased risk to acute myeloid leukemia (AML) progression. [...]

[Bellaterra] : Universitat Autònoma de Barcelona, 2016  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.